Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Publication
, Journal Article
Published in: JCO Precis Oncol
April 2024
Duke Scholars
Published In
JCO Precis Oncol
DOI
EISSN
2473-4284
Publication Date
April 2024
Volume
8
Start / End Page
e2400121
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (2024). JCO Precis Oncol, 8, e2400121. https://doi.org/10.1200/PO.24.00121
“Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” JCO Precis Oncol 8 (April 2024): e2400121. https://doi.org/10.1200/PO.24.00121.
Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2024 Apr;8:e2400121.
“Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” JCO Precis Oncol, vol. 8, Apr. 2024, p. e2400121. Pubmed, doi:10.1200/PO.24.00121.
Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2024 Apr;8:e2400121.
Published In
JCO Precis Oncol
DOI
EISSN
2473-4284
Publication Date
April 2024
Volume
8
Start / End Page
e2400121
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis